Drug major Lupin has opened a research and development (R&D) centre for inhalation products at Coral Springs in Florida, the US. The facility will focus on the R&D of inhalation products for the treatment of asthma, allergic rhinitis, chronic obstructive pulmonary diseases and other lung diseases.
With the talent and resources Florida provides, the company’s Coral Springs expansion will further strengthen its ability to bring quality, affordable pharmaceuticals to patients in the United States and other key markets globally.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.
